Across TCGA pan-cancer cohorts, RPL23AP57 RNA is linked to patient survival in 22 of 34 cancer types, making it the most broadly survival-associated RPL23AP57 data layer.
The strongest signal is observed in ovarian serous cystadenocarcinoma (OV), where higher RPL23AP57 RNA is associated with worse disease-free survival. In most high-consensus cancer types, elevated RPL23AP57 expression acts as an unfavorable survival marker, although some lineages such as CESC and MESO show a favorable association.
OV, ACC, and CESC are the cancer types where RPL23AP57 RNA most reproducibly stratifies survival.
RNA survival associations by lineage
Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.